These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 22493785)

  • 1. Stratified medicine for cancer therapy.
    Shaw EC; Johnson PW
    Drug Discov Today; 2012 Mar; 17(5-6):261-8. PubMed ID: 22493785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth control of normal and malignant lymphocytes--cell death research from basic concepts to signal pathways and translation into the clinic.
    Debatin KM
    Klin Padiatr; 2009; 221(6):332-8. PubMed ID: 19890783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-related networks: a help to understand, predict and change malignant transformation.
    Csermely P; Korcsmáros T
    Semin Cancer Biol; 2013 Aug; 23(4):209-12. PubMed ID: 23831276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Developmental Pathways: The Achilles Heel of Cancer?
    Dempke WCM; Fenchel K; Uciechowski P; Chevassut T
    Oncology; 2017; 93(4):213-223. PubMed ID: 28738360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of cell death and disease: advances in therapeutic intervention.
    Packham G
    Apoptosis; 2003 Jun; 8(3):307-9. PubMed ID: 12766491
    [No Abstract]   [Full Text] [Related]  

  • 6. Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.
    Aguilar BJ; Zhou H; Lu Q
    Curr Med Chem; 2017; 24(32):3485-3507. PubMed ID: 28571533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difluoromethylornithine in cancer: new advances.
    Alexiou GA; Lianos GD; Ragos V; Galani V; Kyritsis AP
    Future Oncol; 2017 Apr; 13(9):809-819. PubMed ID: 28125906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tailoring Ras-pathway--inhibitor combinations for cancer therapy.
    Blum R; Kloog Y
    Drug Resist Updat; 2005 Dec; 8(6):369-80. PubMed ID: 16356760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ERBB network: at last, cancer therapy meets systems biology.
    Yarden Y; Pines G
    Nat Rev Cancer; 2012 Jul; 12(8):553-63. PubMed ID: 22785351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing and optimizing human anticancer drug targets based on topological properties in the context of biological pathways.
    Zhang J; Wang Y; Shang D; Yu F; Liu W; Zhang Y; Feng C; Wang Q; Xu Y; Liu Y; Bai X; Li X; Li C
    J Biomed Inform; 2015 Apr; 54():132-40. PubMed ID: 25724580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phospholipase D and choline kinase: their role in cancer development and their potential as drug targets.
    Rodríguez-González A; Ramírez de Molina A; Benítez-Rajal J; Lacal JC
    Prog Cell Cycle Res; 2003; 5():191-201. PubMed ID: 14593713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell signaling and cancer-possible targets for therapy.
    Wenner CE
    J Cell Physiol; 2010 May; 223(2):299-308. PubMed ID: 20127706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New biomarkers and therapeutics can be discovered during COPD-lung cancer transition.
    Wang X
    Cell Biol Toxicol; 2016 Oct; 32(5):359-61. PubMed ID: 27405768
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting survivin in cancer: the cell-signalling perspective.
    Kanwar JR; Kamalapuram SK; Kanwar RK
    Drug Discov Today; 2011 Jun; 16(11-12):485-94. PubMed ID: 21511051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
    Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
    Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.
    Cha S; Lee J; Shin JY; Kim JY; Sim SH; Keam B; Kim TM; Kim DW; Heo DS; Lee SH; Kim JI
    BMC Cancer; 2016 Feb; 16():170. PubMed ID: 26925973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining imaging and pathway profiling: an alternative approach to cancer drug discovery.
    Carragher NO; Brunton VG; Frame MC
    Drug Discov Today; 2012 Mar; 17(5-6):203-14. PubMed ID: 22493783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Objective assessment of cancer genes for drug discovery.
    Patel MN; Halling-Brown MD; Tym JE; Workman P; Al-Lazikani B
    Nat Rev Drug Discov; 2013 Jan; 12(1):35-50. PubMed ID: 23274470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-Agnostic Drug Development.
    Offin M; Liu D; Drilon A
    Am Soc Clin Oncol Educ Book; 2018 May; 38():184-187. PubMed ID: 30231313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.